Supernus Pharmaceuticals (NASDAQ:SUPN) Raised to Strong-Buy at StockNews.com

StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN - Free Report) from a buy rating to a strong-buy rating in a research note issued to investors on Thursday morning.

Separately, Cantor Fitzgerald reiterated a "neutral" rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

Supernus Pharmaceuticals Trading Up 1.8 %

Shares of SUPN traded up $0.55 on Thursday, reaching $30.84. 354,293 shares of the company's stock traded hands, compared to its average volume of 494,139. The stock's 50 day simple moving average is $32.41 and its two-hundred day simple moving average is $35.01. Supernus Pharmaceuticals has a 52-week low of $25.53 and a 52-week high of $40.28. The stock has a market cap of $1.72 billion, a PE ratio of 28.82 and a beta of 0.90.

Insider Buying and Selling

In related news, VP Padmanabh P. Bhatt sold 700 shares of the firm's stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total value of $27,734.00. Following the completion of the transaction, the vice president now directly owns 10,149 shares of the company's stock, valued at approximately $402,103.38. This trade represents a 6.45 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Jonathan Rubin sold 927 shares of the business's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares in the company, valued at $307,444.95. The trade was a 10.56 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 11,104 shares of company stock valued at $440,263. 9.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SUPN. QRG Capital Management Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 5.5% in the first quarter. QRG Capital Management Inc. now owns 17,583 shares of the specialty pharmaceutical company's stock worth $576,000 after buying an additional 913 shares in the last quarter. Exchange Traded Concepts LLC increased its holdings in Supernus Pharmaceuticals by 12.5% during the 1st quarter. Exchange Traded Concepts LLC now owns 24,881 shares of the specialty pharmaceutical company's stock worth $815,000 after acquiring an additional 2,762 shares during the period. Azzad Asset Management Inc. ADV purchased a new stake in Supernus Pharmaceuticals in the 1st quarter worth approximately $552,000. SG Americas Securities LLC boosted its holdings in Supernus Pharmaceuticals by 63.6% in the 1st quarter. SG Americas Securities LLC now owns 17,671 shares of the specialty pharmaceutical company's stock valued at $579,000 after purchasing an additional 6,867 shares during the period. Finally, Wedge Capital Management L L P NC grew its position in shares of Supernus Pharmaceuticals by 26.2% during the 1st quarter. Wedge Capital Management L L P NC now owns 67,286 shares of the specialty pharmaceutical company's stock valued at $2,204,000 after purchasing an additional 13,955 shares in the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.